Imatinib Stada Arzneimittel (Imatinib)

Imatinib binds to the ATP‑binding pocket of the BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This blockade halts proliferative signaling pathways, leading to reduced tumor cell growth and induction of apoptosis in malignant cells that rely on these kinases for survival.

The dose of Imatinib Stada Arzneimittel is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant therapies. Dosing regimens are established in clinical guidelines and should be followed exactly as directed by the treating oncologist.

Imatinib is classified as contraindicated in pregnancy unless the potential benefit justifies the risk to the fetus, because animal studies have shown teratogenic effects. It is also not recommended during breastfeeding, as the drug can be excreted in milk and may affect the infant. Consultation with a specialist is essential before exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Imatinib Stada Arzneimittel. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard of care for CML and GIST. Newer agents such as dasatinib, nilotinib or ponatinib may offer activity against certain resistant mutations, but Imatinib retains a favorable safety profile and extensive clinical experience. Choice of therapy depends on mutation status, prior treatment, and individual patient factors.

Imatinib Stada Arzneimittel should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original blister or bottle, protect it from moisture, direct sunlight and extreme temperature fluctuations. Do not refrigerate or freeze the tablets, as this could affect their stability.

Imatinib is administered orally, usually as whole tablets swallowed with water. It can be taken with or without food, but consistent intake with respect to meals is recommended to maintain stable absorption. Patients should follow the dosing schedule prescribed by their oncologist and not alter the regimen without medical advice.

Serious adverse events include hepatotoxicity, severe myelosuppression (low blood counts), cardiotoxicity such as reduced left‑ventricular ejection fraction, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for liver enzymes, complete blood counts, cardiac function and any signs of severe skin or respiratory reactions.

Imatinib is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. It should also be avoided in individuals with severe hepatic impairment, uncontrolled cardiac disease, or in those who are pregnant or breastfeeding unless the therapeutic benefit outweighs the potential risk. A thorough medical assessment is required before initiation.